Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Mortality risk after TAVI comparable between patients with tricuspid vs bicuspid aortic valves

11 Jun 2019

The likelihood of postprocedural peacemaker implantation (PMI) and midterm mortality after transcatheter aortic valve implantation (TAVI) is comparable between patients with bicuspid (B-AV) and tricuspid (T-AV) aortic valves, reports a recent meta-analysis.

Researchers accessed the databases of Medline and Embase for studies that compared B-AV and T-AV patients who underwent TAVI. Outcomes included the incidence of postprocedural PMI or transcatheter valve regurgitation (TVR), and early (30-day and in-hospital) or late mortality.

Applying the selection criteria yielded 12 eligible studies with 1,045 B-AV and 4,069 T-AV participants. Compared with T-AV patients, those with B-AV were significantly more likely to develop TVR after TAVI (risk ratio [RR], 1.42, 95 percent CI, 1.11–1.82; Z, 2.76; p=0.006). There was no significant heterogeneity of evidence (p=1.00).

In contrast, the B-AV and T-AV groups were comparable in terms of PMI incidence (RR, 1.07, 0.87–1.32; Z, 0.61; p=0.54), 30-day mortality (RR, 1.35, 0.94–1.93; Z, 1.61; p=0.11) and midterm mortality (1–2-years; RR, 1.00, 0.77–1.31; Z, 0.01; p=0.99).

The researchers then performed meta-regression analysis of six potential confounders: age, B-AV type, mean aortic valve gradient, left ventricular ejection fraction, aortic valve area and aortic valve calcification. All obtained coefficients failed to reach statistical significance, indicating that the effect of B-AV on the outcomes of interest is independent of these confounding factors.

Future meta-analyses that include a larger number of studies of good quality will be helpful in validating the present findings, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.